Oligomerization of Dopamine and Serotonin Receptors

Until recently, it has largely been assumed that G protein-coupled receptors (GPCRs) function as monomeric entities. However, over the past few years, we and others have documented that GPCRs can form dimers and oligomers, leading to a re-evaluation of the mechanisms thought to mediate GPCR function. Despite the growing number of investigations into dimerization, little is known about the structural basis of receptor-receptor interactions and the functional consequences of dimer formation. Here, we present a brief review of some insights we have gained into the dimerization of dopamine and serotonin receptors. We have demonstrated that agonist-regulated trafficking is identical for receptor monomers and dimers, however, agonist treatment appears to stabilise the receptor oligomers. An investigation of the structural assembly between receptors involved in dimerization showed that there are several sites of interaction including hydrophobic transmembrane domain interactions and intermolecular disulphide bonds. We have also examined receptor hetero-oligomerization and demonstrated the potential for novel functions as a result of these associations. Finally, as a result of these observations, we have been able to present evidence that GPCRs function as oligomers in the cell.

[1]  M. Caron,et al.  Phosphorylation and Palmitoylation of the Human D2L Dopamine Receptor in Sf9 Cells , 1994, Journal of neurochemistry.

[2]  H. Akil,et al.  Inhibition of cell surface expression by mutant receptors demonstrates that D2 dopamine receptors exist as oligomers in the cell. , 2000, Molecular pharmacology.

[3]  M. Caron,et al.  Human serotonin1B receptor expression in Sf9 cells: phosphorylation, palmitoylation, and adenylyl cyclase inhibition. , 1993, Biochemistry.

[4]  H. W. Harris,et al.  Disulfide Bonds in the Extracellular Calcium-Polyvalent Cation-sensing Receptor Correlate with Dimer Formation and Its Response to Divalent Cations in Vitro * , 1998, The Journal of Biological Chemistry.

[5]  Trevor Sharp,et al.  A review of central 5-HT receptors and their function , 1999, Neuropharmacology.

[6]  G. Köhr,et al.  Role of heteromer formation in GABAB receptor function. , 1999, Science.

[7]  Alan Wise,et al.  Heterodimerization is required for the formation of a functional GABAB receptor , 1998, Nature.

[8]  J. Morrison,et al.  Expression of Dopamine D3 Receptor Dimers and Tetramers in Brain and in Transfected Cells* , 1997, The Journal of Biological Chemistry.

[9]  L. Gama,et al.  Dimerization of the Calcium-sensing Receptor Occurs within the Extracellular Domain and Is Eliminated by Cys → Ser Mutations at Cys101 and Cys236 * , 1999, The Journal of Biological Chemistry.

[10]  R. Rozmahel,et al.  Characterization of the human 5-hydroxytryptamine1B receptor. , 1992, The Journal of biological chemistry.

[11]  Jilly F. Evans,et al.  Identification of a GABAB Receptor Subunit, gb2, Required for Functional GABAB Receptor Activity* , 1999, The Journal of Biological Chemistry.

[12]  B. Kobilka,et al.  Co-expression of Defective Luteinizing Hormone Receptor Fragments Partially Reconstitutes Ligand-induced Signal Generation* , 1997, The Journal of Biological Chemistry.

[13]  Kenneth A. Jones,et al.  GABAB receptors function as a heteromeric assembly of the subunits GABABR1 and GABABR2 , 1998, Nature.

[14]  L. Uphouse Multiple Serotonin Receptors: Too Many, Not Enough, or Just the Right Number? , 1997, Neuroscience & Biobehavioral Reviews.

[15]  R. Shigemoto,et al.  GABAB-receptor subtypes assemble into functional heteromeric complexes , 1998, Nature.

[16]  Michel Bouvier,et al.  A Peptide Derived from a β2-Adrenergic Receptor Transmembrane Domain Inhibits Both Receptor Dimerization and Activation* , 1996, The Journal of Biological Chemistry.

[17]  B. O'dowd,et al.  Serotonin 5‐HT1B and 5‐HT1D receptors form homodimers when expressed alone and heterodimers when co‐expressed , 1999, FEBS letters.

[18]  T. Gudermann,et al.  Inhibition of gonadotropin-releasing hormone receptor signaling by expression of a splice variant of the human receptor. , 1997, Molecular endocrinology.

[19]  P. Seeman,et al.  A Transmembrane Domain-derived Peptide Inhibits D1 Dopamine Receptor Function without Affecting Receptor Oligomerization* , 1998, The Journal of Biological Chemistry.

[20]  Philip Seeman,et al.  Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine , 1991, Nature.

[21]  S. R. Nash,et al.  Dopamine receptors: from structure to function. , 1998, Physiological reviews.

[22]  P. Bonaventure,et al.  Detailed mapping of serotonin 5-HT1B and 5-HT1D receptor messenger RNA and ligand binding sites in guinea-pig brain and trigeminal ganglion: clues for function , 1997, Neuroscience.

[23]  C. Bergson,et al.  On the origin of mRNA encoding the truncated dopamine D3-type receptor D3nf and detection of D3nf-like immunoreactivity in human brain. , 1994, The Journal of biological chemistry.

[24]  Bruno Giros,et al.  Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA , 1991, Brain Research.

[25]  F. Marshall,et al.  GABAB receptors - the first 7TM heterodimers. , 1999, Trends in pharmacological sciences.

[26]  P. Seeman,et al.  Glycoprotein nature of D2 dopamine receptors , 1988, FEBS letters.

[27]  J. Wess,et al.  Identification and Molecular Characterization of m3 Muscarinic Receptor Dimers* , 1999, The Journal of Biological Chemistry.

[28]  B. O'dowd,et al.  The splice variant D3nf reduces ligand binding to the D3 dopamine receptor: evidence for heterooligomerization. , 2000, Brain research. Molecular brain research.

[29]  A. Spiegel,et al.  Mutational analysis of the cysteines in the extracellular domain of the human Ca2+ receptor: effects on cell surface expression, dimerization and signal transduction , 1998, FEBS letters.

[30]  B. Borowsky,et al.  GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. , 1998, Nature.

[31]  C. Reynolds,et al.  A new approach to docking in the beta 2-adrenergic receptor that exploits the domain structure of G-protein-coupled receptors. , 1997, Journal of medicinal chemistry.

[32]  J. Wess,et al.  Truncated V2 vasopressin receptors as negative regulators of wild-type V2 receptor function. , 1998, Biochemistry.

[33]  P. Seeman,et al.  Resistance of the dopamine D2L receptor to desensitization accompanies the up-regulation of receptors on to the surface of Sf9 cells. , 1997, Endocrinology.

[34]  P. Seeman,et al.  Dopamine D2 receptor dimers and receptor-blocking peptides. , 1996, Biochemical and biophysical research communications.

[35]  C. Romano,et al.  Metabotropic Glutamate Receptor 5 Is a Disulfide-linked Dimer* , 1996, The Journal of Biological Chemistry.

[36]  Lakshmi A. Devi,et al.  G-protein-coupled receptor heterodimerization modulates receptor function , 1999, Nature.

[37]  J. Stevens,et al.  Agonist-induced desensitization of dopamine D1 receptor-stimulated adenylyl cyclase activity is temporally and biochemically separated from D1 receptor internalization. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[38]  P. Seeman,et al.  Dopamine D2 receptor dimers in human and rat brain , 1998, FEBS letters.

[39]  Kuan-Teh Jeang,et al.  Mechanism of Transdominant Inhibition of CCR5-mediated HIV-1 Infection by ccr5Δ32* , 1997, The Journal of Biological Chemistry.

[40]  L. Devi,et al.  Dimerization of the delta opioid receptor: implication for a role in receptor internalization. , 1997, The Journal of biological chemistry.

[41]  V C Emery,et al.  Baculovirus expression vectors. , 1991, Methods in molecular biology.

[42]  T. Ezashi,et al.  Suppression of Prostaglandin E Receptor Signaling by the Variant Form of EP1 Subtype* , 1996, The Journal of Biological Chemistry.

[43]  M. Caron,et al.  Desensitization, phosphorylation and palmitoylation of the human dopamine D1 receptor. , 1994, European journal of pharmacology.